Biological assessment criteria during antagonist protocols;Critères d'évaluation biologique au cours des protocoles antagonistes

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 33, Issue 6 II, 2004, Pages

  Plachot, M ^a  

^a Centre Hospitalier Intercommunal Jean Rostand   (France)

Author keywords

Antagonists; Human embryo; Human oocyte

Indexed keywords

CETRORELIX; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; TRIPTORELIN;

FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE RELEASE; NIDATION; OOCYTE MATURATION; OVULATION INDUCTION; PREGNANCY RATE; REVIEW;

ANOVULATION; CLINICAL PROTOCOLS; DRUG MONITORING; FEMALE; FERTILITY; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; LUTEINIZING HORMONE; OOCYTES; OOGENESIS; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE;

EID: 5644244340     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P, Frydman R. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314-20.
2. Roulier R, Chabert-Orsini V, Sitri MC, Barry B, Terriou P. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment. Reprod Biomed Online 2003; 7: 185-9.
3. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmuller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Hum Reprod 1994; 9: 788-91.
4. Imthurn B, Macas E, Rosselli M, Keller PJ. Nuclear maturity and oocyte morphology after stimulation with highly purified follicle stimulating hormone compared to human menopausal gonadotrophin. Hum Reprod 1996; 11: 2387-91.
5. Maclellan LJ, Whyte TR, Murray A, Fitzpatrick LA, Earl CR, Aspden WJ, Kinder JE, Grotjan HE, Walsh J, Trigg TE, D'Occhio MJ. Superstimulation of ovarian follicular growth with FSH oocyte recovery, and embryo production from Zebu (Bos indicus) calves: effects of treatment with a GnRH agonist or antagonist. Theriogenology 1998; 49: 1317-29.
6. Oussaid B, Lonergan P, Khatir H, Guler A, Monniaux D, Touze JL, Beckers JF, Cognie Y, Mermillod P. Effect of GnRH antagonist-induced prolonged follicular phase on follicular atresia and oocyte developmental competence in vitro in superovulated heifers. J Reprod Fertil 2000; 118: 137-44.
7. Hernandez ER. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000; 15: 1211-6.
8. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone, (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000; 15: 526-31.